SAFETY AND EFFICACY OF TOCILIZUMAB (ANTI-IL6R, TCZ) THERAPY IN THE TREATMENT OF CHRONIC ANTIBODY MEDIATED REJECTION (CABMR) IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS.

被引：0
|
作者：
Puliyanda, D. [1 ]
Kim, I. [2 ]
Choi, J. [2 ]
Haas, M. [2 ]
Zhang, X. [2 ]
Vo, A. [2 ]
Pizzo, H. [1 ]
Jordan, S. [2 ]
机构：
[1] Cedars Sinai Med Ctr, Pediat Nephrol, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
来源：
PEDIATRIC TRANSPLANTATION | 2017年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
201.5
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [21] Successful treatment with IVIG and rituximab for treatment of chronic antibody-mediated rejection in pediatric renal transplant recipients
    Billing, H.
    Suesal, C.
    Ovens, J.
    Waldherr, R.
    Opelz, G.
    PEDIATRIC NEPHROLOGY, 2011, 26 (09) : 1616 - 1616
  • [22] Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR).
    Patel, S.
    Mohan, S.
    Fernandez, H.
    Batal, I.
    Ratner, L.
    Crew, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 326 - 326
  • [23] Anti-IL-6 Receptor (Anti-IL6R) Treatment Is Effective in Reducing Recall Antibody Responses in Sensitized HLA-A2 Skin Graft Recipients.
    Jordan, S.
    Wu, G.
    Chai, N.
    Kim, I.
    Klein, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 548 - 548
  • [24] Effectiveness of Rituximab and Intravenous Immunoglobulin for the Treatment of Chronic Antibody Mediated Rejection in Kidney Transplant Recipients.
    An, G.
    Chung, B.
    Park, C.
    Choi, B.
    Kim, Y.
    Yang, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 328 - 328
  • [25] Extended Experience with IVIG and Rituximab for Treatment of Chronic Antibody-Mediated Rejection in Pediatric Renal Transplant Recipients
    Billing, H.
    Suesal, C.
    Ovens, J.
    Waldherr, R.
    Opelz, G.
    Toenshoff, B.
    PEDIATRIC NEPHROLOGY, 2010, 25 (09) : 1814 - 1814
  • [26] Extended Experience with IVIG and Rituximab for Treatment of Chronic Antibody-Mediated Rejection in Pediatric Renal Transplant Recipients
    Billing, Heiko
    Suesal, Caner
    Ovens, Joerg
    Waldherr, Ruediger
    Opelz, Gehard
    Toenshoff, Burkhard
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 416 - 416
  • [27] Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients
    Pearl, Meghan
    Weng, Patricia L.
    Chen, Lucia
    Dokras, Aditi
    Pizzo, Helen
    Garrison, Jonathan
    Butler, Carrie
    Zhang, Jennifer
    Reed, Elaine F.
    Kim, Irene K.
    Choi, Jua
    Haas, Mark
    Zhang, Xiaohai
    Vo, Ashley
    Chambers, Eileen Tsai
    Ettenger, Robert
    Jordan, Stanley
    Puliyanda, Dechu
    CLINICAL TRANSPLANTATION, 2022, 36 (08)
  • [28] SUCCESSFUL TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS WITH IVIG AND RITUXIMAB: A PROSPECTIVE STUDY
    Billing, Heiko
    Suesal, Caner
    Ovens, Joerg
    Waldherr, Ruediger
    Opelz, Gerhard
    Toenshoff, Burkhard
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 139 - 139
  • [29] Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients
    Choi, J.
    Aubert, O.
    Vo, A.
    Loupy, A.
    Haas, M.
    Puliyanda, D.
    Kim, I.
    Louie, S.
    Kang, A.
    Peng, A.
    Kahwaji, J.
    Reinsmoen, N.
    Toyoda, M.
    Jordan, S. C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (09) : 2381 - 2389
  • [30] Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients.
    Kincaide, E.
    Hitchman, K.
    Hall, R.
    Yamaguchi, I.
    Crowther, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 705 - 706
12345